Revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
uniQure N.V. (QURE)
Price$44.50Cached quote
Net income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.1M | $27.1M | $15.8M | $106.5M | $524.0M | $37.5M | $7.3M | $11.3M | $13.1M | $25.1M | $10.6M | $6.1M |
| Gross profit | $14.4M | $25.9M | $15.8M | $105.2M | $499.0M | $34.6M | $5.6M | $10.1M | $12.3M | $23.8M | — | — |
| Gross margin | 89.53% | 95.33% | 99.59% | 98.82% | 95.23% | 92.27% | 77.28% | 89.35% | 93.77% | 94.63% | — | — |
| Research & development | $140.7M | $143.8M | $214.9M | $197.6M | $143.5M | $122.4M | $94.7M | $74.8M | $72.2M | $72.5M | $59.1M | $43.8M |
| Operating expenses | $199.8M | $210.1M | $289.5M | $252.7M | $199.8M | $165.0M | $128.3M | $100.1M | $96.8M | $98.5M | $82.5M | $60.8M |
| Operating income | −$185.3M | −$184.3M | −$282.9M | −$143.2M | $310.6M | −$125.4M | −$121.1M | −$88.2M | −$71.3M | −$71.9M | −$71.2M | −$53.7M |
| Operating margin | −1,151.38% | −679.58% | −1,785.46% | −134.44% | 59.28% | −334.34% | −1,663.78% | −781.92% | −544.31% | −286.66% | −672.63% | −874.16% |
| EBITDA | −$170.6M | −$171.7M | −$271.0M | −$134.6M | $317.9M | −$114.8M | −$114.5M | −$75.8M | −$63.8M | −$66.4M | −$66.8M | −$51.7M |
| EBITDA margin | −1,059.70% | −632.96% | −1,710.35% | −126.43% | 60.67% | −305.96% | −1,572.19% | −671.90% | −486.76% | −264.75% | −631.04% | −841.59% |
| Net income | −$199.0M | −$239.6M | −$308.5M | −$126.8M | $329.6M | −$125.0M | −$124.2M | −$83.3M | −$79.3M | −$73.4M | −$82.1M | — |
| Net profit margin | −1,236.00% | −883.35% | −1,947.09% | −119.07% | 62.90% | −333.27% | −1,705.82% | −738.25% | −604.72% | −292.35% | −775.98% | — |
| Basic EPSper basic share | -$3.46 | -$4.92 | -$6.47 | -$2.71 | $7.17 | -$2.81 | -$3.11 | -$2.34 | -$2.94 | -$2.93 | -$3.72 | -$2.91 |
| Diluted EPSper diluted share | -$3.46 | -$4.92 | -$6.47 | -$2.71 | $7.04 | -$2.81 | -$3.11 | -$2.34 | -$2.94 | -$2.93 | -$3.72 | -$2.91 |
Owners
Reported shareholders
9.70%of listed shares
Avoro Capital Advisors LLC6.73M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Avoro Capital Advisors LLC | 9.70%6.73M shares |
JPMORGAN CHASE & CO | 7.02%4.87M shares |
RTW INVESTMENTS, LP | 5.68%3.94M shares |
STATE STREET CORP | 4.19%2.9M shares |
Aberdeen Group plc | 4.11%2.85M shares |
BlackRock, Inc. | 2.71%1.88M shares |
ORBIMED ADVISORS LLC | 2.61%1.81M shares |
JANE STREET GROUP, LLC | 2.32%1.61M shares |
JENNISON ASSOCIATES LLC | 2.25%1.56M shares |
Boxer Capital Management, LLC | 2.17%1.5M shares |
GOLDMAN SACHS GROUP INC | 2.13%1.48M shares |
TWO SIGMA INVESTMENTS, LP | 2.11%1.46M shares |
Two Seas Capital LP | 2.08%1.44M shares |
FMR LLC | 1.83%1.27M shares |
MAK CAPITAL ONE LLC | 1.78%1.23M shares |
MPM BIOIMPACT LLC | 1.77%1.23M shares |
MORGAN STANLEY | 1.54%1.07M shares |
Assenagon Asset Management S.A. | 1.48%1.03M shares |
Vestal Point Capital, LP | 1.35%935K shares |
MAVERICK CAPITAL LTD | 1.33%925.38K shares |
Percentages use 69.33M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 26, 2026Form 4 | Abi-Saab WalidChief Medical Officer | SellOrdinary Shares | 1.4K | $46.86 | $67.2K | 168.2K |
| Jun 25, 2026Form 4 · 10b5-1 | Kapusta Matthew CCEO, Managing Director | SellOrdinary Shares | 28.7K | $50.02 | $1.44M | 519.2K |
| Jun 24, 2026Form 4 · 10b5-1 | Kapusta Matthew CCEO, Managing Director | SellOrdinary Shares | 6.7K | $50.00 | $334.8K | 519.2K |
| Jun 18, 2026Form 4 · 10b5-1 | Kapusta Matthew CCEO, Managing Director | SellOrdinary Shares | 37.0K | $50.00 | $1.85M | 521.8K |
| Jun 18, 2026Form 4 · 10b5-1 | Kapusta Matthew CCEO, Managing Director | SellOrdinary Shares | 4.7K | $50.00 | $232.8K | 558.8K |
Community posts
uniQure reports longer Huntington’s follow-up, with mixed statistical results
uniQure ($QURE) released additional Phase I/II results for AMT-130 in Huntington’s disease. Among 15 high-dose patients followed for 36 months, the company reported 80% slower decline on the composite disease-rating scale against an externa ...
